W. Victor R. Vieweg, MD Professor of psychiatry and internal medicine Medical College of Virginia Virginia Commonwealth University, Richmond
Robert A. Adler, MD Professor of internal medicine Medical College of Virginia Virginia Commonwealth University Chief of Endocrinology Service McGuire VA Medical Center, Richmond
Antony Fernandez, MD Assistant clinical professor of psychiatry Medical College of Virginia Virginia Commonwealth University Psychiatry Service, McGuire VA Medical Center, Richmond
References
5.51 kg with a placebo
4.41 kg with low-dose nizatidine
2.76 kg with high-dose nizatidine (p =0.02 compared with a placebo).
In the high-dose nizatidine group, only 6% of patients gained more than 10 kg, and weight gain leveled off by week eight. Adverse events and clinical improvements were similar in the three groups.
Related resources
Weight gain: A growing problem in schizophrenia management. J Clin Psychiatry 2001;62(suppl 7).
Weight gain associated with the use of psychotropic medications. J Clin Psychiatry 1999;60(suppl 2).
Effects of atypical antipsychotics on body weight and glucose regulation. J Clin Psychiatry 2001;62(suppl 23).
National Heart, Lung, and Blood Institute. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. www.nhlbi.nih.gov/guidelines/obesity/ob_home.htm
Drug brand names
Amantadine • Symmetrel
Clozapine • Clozaril
Nizatidine • Axid
Olanzapine • Zyprexa
Orlistat • Xenical
Quetiapine • Seroquel
Risperidone • Risperdal
Sibutramine • Meridia
Topiramate • Topamax
Ziprasidone • Geodon
Disclosure
The authors report no financial relationship with any company whose products are mentioned in this article.
